Phenotypic Precision Medicine in Advanced Prostate Cancer
Advertisement
Latest News
Video Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Drs. Chang and Joyce consider the role that N-803 now plays within the treatment paradigm for BCG-unresponsive bladder CIS.
Drs. Chang, Joyce take a look at QUILT-3.032, including complete responses to N-803 plus BCG in BCG-unresponsive bladder CIS.
Dr. Daneshmand discusses some of the designs and results of ADVANCED-2, PIVOT-006, ABLE-22, and more.
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Advertisement
Advertisement
Trending
Rana McKay, MD, GU Medical Oncologist from UCSD, gives her outlook on the future of prostate cancer care in the year 2025.
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.